Silodosin Capsule
Product Images NDC 72205-010

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Silodosin (NDC 72205-010). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Novadoz Pharmaceuticals Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

4mg-30s (Silodosin 4mg 30s Container Label)

Silodosin Capsules 4 mg oral capsules label with package information. The label shows 30 capsules per container, manufacturer MSN Laboratories Private Limited, and distributor Novadoz Pharmaceuticals LLC. It includes dosage details, storage instructions, and barcodes. The label prominently features the 4 mg strength and Novadoz branding.*

FDA Label Image

8mg-30s (Silodosin 8mg 30s Container Label)

Silodosin Capsules 8 mg oral capsules label from Novadoz Pharmaceuticals LLC. The label indicates a package of 30 capsules with the National Drug Code (NDC) 72205-010-30. It includes storage instructions, manufacturing and distribution details, and a barcode.*

FDA Label Image

8mg-90s (Silodosin 8mg 90s Container Label)

Label for Silodosin Capsules 8 mg, oral capsules, in a 90-capsule package. Distributed by Novadoz Pharmaceuticals LLC, Piscataway, NJ. Manufactured by MSN Laboratories Private Limited, India. The label includes dosage, storage instructions, and contact information.*

FDA Label Image

Figure-01 (Silodosin Figure 01)

A pharmacokinetic curve showing silodosin concentration (ng/mL) over time (hours) after administration. The graph plots silodosin plasma levels, peaking around 3 hours, and then gradually decreasing over 24 hours. Error bars indicate variability at each time point.*

FDA Label Image

Fig-2 (Silodosin Figure 02)

A line graph comparing the change from baseline in IPSS Total Score over time between Silodosin 8 mg and Placebo. The x-axis represents days, including baseline, 3.5, 7, 14, 28, and 84/LOCF, while the y-axis shows the change in score with negative values indicating improvement. Silodosin 8 mg shows a greater decrease in IPSS score compared to placebo throughout the study period.*

FDA Label Image

Fig-3 (Silodosin Figure 03)

This line graph shows the change from baseline in IPSS Total Score over a period of days for two groups: Placebo and Silodosin 8 mg. The x-axis represents days, and the y-axis represents change from baseline. Silodosin 8 mg consistently shows a greater decrease in score compared to placebo throughout the time points measured, indicating a treatment effect plotted over time.*

FDA Label Image

Fig-4 (Silodosin Figure 04)

Line graph showing change from baseline in Qmax (mL/sec) over time in days for Silodosin 8 mg capsules and placebo. The graph plots mean changes with Silodosin 8 mg showing higher Qmax values compared to placebo up to 84 days/LOCF. Statistical significance (p<0.05) is noted between groups.*

FDA Label Image

Fig-5 (Silodosin Figure 05)

A line graph illustrating the change from baseline in Qmax (mL/sec) over time for Silodosin 8 mg compared to placebo. The x-axis shows days from baseline (B) through 84/LOCF, while the y-axis measures change in Qmax. Silodosin 8 mg is represented by a solid line with circles; placebo by a line with open triangles. The graph indicates statistical significance at p<0.05.*

FDA Label Image

Structure (Silodosin Structure)

Chemical structure of silodosin, showing its detailed molecular arrangement including aromatic rings, amide, ether, trifluoromethyl group, and hydroxyl functional groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.